Group 1 - The Hang Seng Index fell by 0.66%, down 165 points, closing at 24,916 points, while the Hang Seng Tech Index dropped by 0.99% [1] - The early trading volume in Hong Kong stocks reached HKD 112.6 billion [1] - President Trump signed an executive order allowing alternative assets like private equity, real estate, and cryptocurrencies to enter 401K retirement savings plans, potentially opening up about USD 12.5 trillion in retirement account funds [1] Group 2 - Cryptocurrency-related stocks surged, with notable increases in prices: 嘉实以太币 (03179) up 6.48%, 博时以太币 (03009) up 6.24%, 华夏以太币 (03046) up 6.13%, and 博雅互动 (00434) up 6.46% [1] - 阜博集团 (03738) saw a significant rise of over 16%, with its stock price increasing by over 50% this week as the company expands into content industry RWA business [1] - 歌礼制药-B (01672) increased by 7.65% as ASC30 completed patient enrollment in Phase IIa, with strong business development expectations [1] - 君实生物 (01877) rose by 6.5% due to improved market conditions in the PD-(L)1/VEGF sector [1] Group 3 - RAFFLESINTERIOR (01376) resumed trading with an 80% surge after a change in controlling interest and a 43.1% discount on a full acquisition offer [2] - 老铺黄金 (06181) increased by 2.96% after being included in the MSCI China Index, with changes effective at the end of the month [2] Group 4 - 北海康成-B (01228) rose by over 30%, with a cumulative increase of nearly 9 times since early June, driven by the potential of the drug维拉苷酶β for significant business development opportunities [3] - 东风集团股份 (00489) saw an early morning increase of over 8%, despite a more than 90% year-on-year decline in net profit for the first half, managing to turn a profit compared to the previous quarter [4] - 和黄医药 (00013) dropped over 15% in early trading, with a 9.2% year-on-year decline in mid-term revenue, although selling joint venture equity led to a more than 16-fold increase in net profit [4]

Market Overview - The Hang Seng Index fell by 0.66%, down 165 points, closing at 24,916 points, while the Hang Seng Tech Index dropped by 0.99% [1] - Early trading in Hong Kong saw a turnover of HKD 112.6 billion [1] Alternative Assets and Cryptocurrency - U.S. President Trump signed an executive order allowing alternative assets such as private equity, real estate, and cryptocurrencies to enter 401K retirement savings plans, potentially opening up approximately USD 12.5 trillion in retirement account funds for these sectors [1] - Cryptocurrency-related stocks and ETFs surged, with notable increases in prices: - Jia Shi Ether (03179) rose by 6.48% - Bosera Ether (03009) increased by 6.24% - Huaxia Ether (03046) gained 6.13% - Boya Interactive (00434) climbed by 6.46% [1] Company Performance Highlights - Fubo Group (03738) saw a significant increase of over 16%, with a cumulative rise of over 50% this week as the company expands its content industry RWA business [1] - Gilead Sciences-B (01672) rose by 7.65% following the completion of patient enrollment in the IIa phase of ASC30, with strong business development expectations [2] - Junshi Biosciences (01877) increased by 6.5% due to improved market conditions in the PD-(L)1/VEGF sector [3] - Raffles Interior (01376) surged by 80% upon resuming trading after a change in controlling interest, with a buyout offer at a discount of approximately 43.1% [4] - Laopu Gold (06181) rose by 2.96% after being included in the MSCI China Index, with changes effective at the end of this month [5] - Beihai Kangcheng-B (01228) increased by over 30%, with a cumulative rise of nearly 9 times since early June, driven by potential significant business development opportunities for Vilazodone [6] - Dongfeng Motor Group (00489) saw an early morning increase of over 8%, despite a more than 90% year-on-year decline in net profit for the first half, managing to turn a profit compared to the previous quarter [7] - Hutchison Whampoa (00013) experienced a drop of over 15% in early trading, with a 9.2% year-on-year decline in mid-term revenue, although selling joint venture equity led to a net profit increase of over 16 times [8]

东吴证券指出，ASC30作为歌礼制药的核心管线，此前在美国开展的口服剂型Ia期临床读出了优秀的疗 效数据，4周最高减重6.5%，而与礼来同赛道的口服小分子GLP-1管线Orforglipron的4周最高减重3.4%相 比效果更佳，具有较高的全球BIC潜力。该行指出，歌礼制药对于ASC30的临床推进速度很快，整体效 率更高，且临床在美国开展，数据更受海外MNC认可。综合以上优势，认为该管线具有很强的BD预 期，随着25年Q4的临床数据读出，BD预计有望推进加快。 本文源自：智通财经网 智通财经获悉，歌礼制药-B(01672)再涨超7%，截至发稿，涨7.14%，报12.76港元，成交额1.28亿港 元。 消息面上，8月5日，歌礼制药宣布，其小分子GLP-1管线ASC30在美国进行的每日口服剂型减重适应症 13周IIa期研究已经完成入组，总计125名患者，预计将在2025年Q4读出顶线数据。ASC30拥有美国和全 球化合物专利保护，专利保护期至2044年。 ...

东吴证券指出，ASC30作为歌礼制药的核心管线，此前在美国开展的口服剂型Ia期临床读出了优秀的疗 效数据，4周最高减重6.5%，而与礼来同赛道的口服小分子GLP-1管线Orforglipron的4周最高减重3.4%相 比效果更佳，具有较高的全球BIC潜力。该行指出，歌礼制药对于ASC30的临床推进速度很快，整体效 率更高，且临床在美国开展，数据更受海外MNC认可。综合以上优势，认为该管线具有很强的BD预 期，随着25年Q4的临床数据读出，BD预计有望推进加快。 消息面上，8月5日，歌礼制药宣布，其小分子GLP-1管线ASC30在美国进行的每日口服剂型减重适应症 13周IIa期研究已经完成入组，总计125名患者，预计将在2025年Q4读出顶线数据。ASC30拥有美国和全 球化合物专利保护，专利保护期至2044年。 歌礼制药-B(01672)再涨超7%，截至发稿，涨7.14%，报12.76港元，成交额1.28亿港元。 ...

Market Performance - US stock indices showed mixed results overnight, with the Chinese concept index rising by 0.95% [1] - Hong Kong's three major indices opened lower, with the Hang Seng Index down by 0.45%, the National Index down by 0.55%, and the Hang Seng Tech Index down by 0.83% [1] Sector Performance - Major technology stocks generally declined, with NetEase down by 1.45% and Baidu down by 1.2%. Other companies like Xiaomi, Meituan, Kuaishou, and Alibaba also saw losses [1] - Biopharmaceutical stocks collectively fell, with Zai Lab experiencing a significant drop of 10%, leading the decline among innovative drug stocks. Other companies like Hutchison China MediTech, Galmed Pharmaceuticals, BeiGene, and WuXi AppTec also faced declines [1] - Semiconductor stocks decreased, with leading company SMIC dropping nearly 4% post-earnings [1] - Shipping, gaming, insurance, oil, and automotive stocks mostly declined, while brain-computer interface concept stocks opened slightly lower, with Nanjing Panda Electronics down nearly 1% [1] Commodity and New Consumption Stocks - Spot gold prices surpassed $3,400 per ounce for the first time since July 23, leading to a rally in gold stocks. Chifeng Jilong Gold Mining rose nearly 5%, with Tongguan Gold, Shandong Gold, and Lingbao Gold also showing significant gains [1] - New consumption concept stocks generally rose, with the "king of stocks" Laopu Gold increasing by 2.45%, and both Nayuki's Tea and Pop Mart also seeing gains [1]

Core Viewpoint - The company is advancing its clinical pipeline, particularly ASC30, which has shown promising results in weight loss and is expected to generate top-line data by Q4 2025 [1][2]. Group 1: ASC30 Clinical Trials - The ASC30 oral formulation has completed enrollment in a 13-week Phase IIa study with 125 patients, aiming to read out top-line data in Q4 2025 [1]. - ASC30 has U.S. and global compound patent protection until 2044, excluding any patent extensions [1]. - The Phase IIa study is randomized, double-blind, placebo-controlled, and multi-center, targeting overweight individuals with at least one weight-related comorbidity [1]. Group 2: Efficacy and Comparison - In a previous Phase I trial in the U.S., ASC30 demonstrated excellent pharmacokinetics and efficacy, achieving a maximum weight loss of 6.5% over four weeks, outperforming Eli Lilly's Orforglipron, which achieved 3.4% [2]. - The ASC30 subcutaneous injection formulation has also commenced its first patient dosing in the U.S. Phase IIa trial, showing a half-life of up to 36 days, which is advantageous compared to Amgen's AMG133 [2]. Group 3: Additional Pipeline Potential - The company has several other promising pipelines, including ASC47, which targets THR-β for fat reduction and muscle gain, and ASC50, an oral IL-17 small molecule for psoriasis treatment [3]. - ASC47's unique mechanism may enhance weight loss effects while mitigating muscle loss side effects when used in conjunction with GLP-1 drugs [3]. - ASC50 is one of the few oral IL-17 small molecules in clinical stages, potentially offering a competitive edge in the psoriasis market [3]. Group 4: Financial Outlook - The company maintains its revenue forecasts for 2025-2027 at 0, 0.4, and 1 billion RMB, respectively [3]. - The target price has been raised to 14.02 RMB based on the FCFF valuation model, with a "buy" rating maintained [3].

Macro Strategy - The report analyzes three historical cases of capacity adjustment over a century, providing insights into supply-demand rebalancing: the long depression in the late 19th century in Europe and America, the 1929 Great Depression, and Japan's capacity reduction in the 1970s and 1990s [1][11] - Key conclusions include that capacity imbalance can lead to a negative feedback loop lasting 20-30 years if uncontrolled, and government intervention is more effective than non-intervention in addressing capacity imbalances [1][11] - Effective supply-demand rebalancing requires simultaneous efforts in controlling capacity, restoring credit, and stabilizing employment, rather than relying solely on supply or demand policies [1][11] Fixed Income - The report discusses the micro-guided convertible bond, which has a total issuance scale of 1.17 billion yuan, with net proceeds used for the construction of an intelligent factory for semiconductor thin film deposition equipment [2][12] - The expected listing price range for the convertible bond is between 128.84 and 143.03 yuan, with a predicted subscription rate of 0.0036% [2][12] - The company, Micro-Guided Nano, has shown steady revenue growth with a compound annual growth rate of 71.44% from 2020 to 2024, achieving 2.7 billion yuan in revenue in 2024, a year-on-year increase of 60.74% [2][12] Industry Analysis - The report on Chuanfeng Power highlights the company's leading position in the all-terrain vehicle and motorcycle markets, with three major business segments experiencing rapid growth [3][14] - The investment recommendation maintains a "buy" rating for Chuanfeng Power, anticipating higher valuations due to its significant market position and growth potential across its business segments [3][14] - Jiuhua Tourism is positioned to leverage its unique cultural and natural resources, with projected net profits of 220 million, 240 million, and 270 million yuan from 2025 to 2027, corresponding to price-earnings ratios of 18, 16, and 15 times [4][14] Company-Specific Insights - Crystal Technology has secured a significant contract for drug discovery, with potential payments exceeding 5.89 billion USD, indicating strong future growth prospects [5][16] - The company is expected to achieve revenues of 552 million, 924 million, and 1.503 billion yuan from 2025 to 2027, with a forecasted return to profitability by 2027 [5][16] - Zhongchong Co., a leader in the pet food industry, reported a 42.6% year-on-year increase in net profit for the first half of 2025, driven by strong growth in its proprietary brands [17][18]

Group 1: Clinical Trial Progress - ASC30's Phase IIa trial in the US has completed patient enrollment, with data expected in Q4 2025[2] - The trial involves 125 participants, all of whom are either obese (BMI ≥ 30 kg/m²) or overweight with at least one weight-related comorbidity (27 kg/m² ≤ BMI < 30 kg/m²)[2] - The primary endpoint is the percentage change in average weight from baseline at week 13[2] Group 2: Product Efficacy and Market Position - ASC30 demonstrated a 6.5% average weight reduction relative to baseline over a 4-week treatment period in the Phase Ib trial[3] - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered both as a monthly injection and a daily oral tablet for obesity treatment[3] - The company holds global compound patent protection until 2044, enhancing its competitive edge in the obesity treatment market[3] Group 3: Future Prospects and Recommendations - The company is positioned as an innovative biotech firm with a strong pipeline, including ASC30 and ASC47 for obesity treatment[4] - ASC40's Phase III trial data is expected in June 2025, showing significant efficacy compared to existing therapies[4] - The company has sufficient cash reserves to support multiple ongoing research projects, indicating a robust financial position[4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The ASC30 pipeline has successfully completed patient enrollment for the Phase IIa trial, with top-line data expected in Q4 2025. This compound has patent protection in the U.S. and globally until 2044 [7] - ASC30 has shown superior efficacy in previous trials, achieving a maximum weight loss of 6.5% over four weeks, outperforming a competitor's product [7] - The company has multiple promising pipelines, including ASC47 and ASC50, which are expected to have strong business development potential [7] - Revenue forecasts for 2025-2027 are projected at 0, 0.4, and 1 billion RMB respectively, with an updated target price of 14.02 RMB [7] Financial Summary - Total revenue for 2023 is projected at 566.9 million RMB, with a significant decline expected in 2024 [1] - The company is expected to incur net losses, with a projected net profit of -300.94 million RMB in 2024 and -454.44 million RMB in 2025 [1] - The price-to-earnings ratio is forecasted to improve from -49.48 in 2023 to -15.76 in 2025 [1][8]

隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开，恒指跌0.15%，国 指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中，百度跌超1%，阿 里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强，与DoveTree完成总 订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、远大医药、金斯瑞 生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨日上涨。另一方 面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下跌。(格隆汇) 相关事件 港股收评：恒生指数涨0.62%！光伏、钢铁成亮点，军工、芯片股表现疲软 港股收评：恒生指数跌 0.56%！内房股、汽车股低迷，黄金股逆势爆发 港股收评：三大指数涨跌不一，恒生科技指数涨 0.56%，医药、军工、汽车大涨 港股收评：恒指再度失守24000，恒生科技指数跌0.33%，医药、芯片、 券商大涨居前 ...